Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement

Key Highlights

• SER shares climbed 39.45% in extended trading, reaching $1.78 from the regular session’s $1.28 close.
• A private placement totaling $15 million is scheduled to finalize on March 20, with an additional $15 million tranche possible by April 30.
• Accompanying warrants could generate as much as $33.3 million in extra capital, potentially funding operations through H2 2027.
• Shares were offered at $2.25 each — representing a 68% markup over the March 17 closing price.
• Greg Bailey, a board member with ties to major Pfizer acquisitions including Biohaven ($11.6B) and Medivation ($14B), assumes Co-Chairman role.

Serina Therapeutics (SER) experienced a dramatic after-hours rally Wednesday, climbing nearly 40% following the announcement of a private financing arrangement with the potential to generate up to $63.3 million.

Serina Therapeutics, Inc., SER

The substantial price movement occurred during extended trading hours when Serina disclosed that an initial $15 million funding tranche is set to finalize on March 20, 2026. The company also expects a subsequent tranche of up to $15 million to close by the end of April.

Shares rose from their regular trading close of $1.28 — which represented a 4.48% decline for the day — to $1.78 in after-hours activity.

The financing carries a $2.25 price per share, marking a substantial 68% premium above the March 17 closing price. Each unit consists of one share or pre-funded warrant alongside a half-warrant entitling holders to purchase additional stock at $5.00 per share. With a four-year exercise period, full warrant execution could yield another $33.3 million, bringing total potential capital raised to $63.3 million.

For a clinical-stage biotechnology firm, this capital infusion is significant. According to Serina, the financing should support operations well into the second half of 2027.

Veteran Biotech Investor Joins Leadership

The financing round is being spearheaded by Greg Bailey, M.D., a current board member who will transition into the role of Co-Chairman alongside current chair Simba Gill, Ph.D.

Bailey’s credentials carry considerable weight in the biotech investment community. He was an early supporter of Biohaven Ltd., which Pfizer acquired in 2022 for approximately $11.6 billion, as well as Medivation, purchased by Pfizer in 2016 for $14 billion.

Investors clearly took notice of Bailey’s involvement. Having a financier with his track record leading a private placement can significantly influence market sentiment in the biotechnology sector.

Capital Allocation Strategy

The raised funds are designated for Serina’s SER-252 registrational program, an active Phase 1b clinical trial focused on treating advanced Parkinson’s disease. Patient enrollment is currently underway at multiple clinical sites spanning Australia and the United States.

SER-252 is advancing through the FDA’s 505(b)(2) regulatory framework, which CEO Steve Ledger characterized as “capital-efficient.” The trial has already administered its first patient dose.

The company anticipates that safety data from Cohort 1 will enable progression to Cohort 2 by Q3 2026. Topline readouts from the single-ascending dose portion of the study are projected for the first half of 2027.

The therapeutic candidate addresses a patient population of roughly 250,000 individuals with advanced Parkinson’s disease in the United States and Europe who continue to experience insufficient symptom management with existing treatment options.

Despite Wednesday’s after-hours surge, SER’s broader performance paints a challenging picture. The stock trades within a 52-week range of $1.22 to $7.92 and has dropped 71.11% over the trailing twelve months. The company maintains a modest market capitalization of just $13.65 million, while its Relative Strength Index registers at 29.86 — indicating deeply oversold conditions.

SER concluded Wednesday’s regular trading session at $1.28, down 4.48% for the day.

The post Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement appeared first on Blockonomi.